Tech Company Financing Transactions

UNITY Biotechnology Funding Round

On 10/31/2016, UNITY Biotechnology landed $116 million in Series B investment from Arch Venture Partners, Bezos Expeditions and Fidelity Management & Research Company.

Transaction Overview

Company Information

Company Status

Publicly-held

Industry

Biopharmaceutical

Mailing Address

3280 Bayshore Blvd. 100
Brisbane, CA 94005
USA

Phone

650-416-1192

Website

www.unitybiotechnology.com

Email Address

[email protected]

Overview

Unity Biotechnology (Nasdaq: UBX) Imagine a future in which you age, but without the diseases your parents got. A future in which it doesn't hurt to grow old. At UNITY, we design therapeutics that prevent, halt, or reverse diseases of aging. Our medicines are designed to lengthen healthspan, the amount of time you live in good health.

Profile

Social Media

Company News

Facebook

YouTube

Management Team

Title

Name

Email & Social

Chief Executive Officer

Keith Leonard

        

Chief Financial Officer

Robert Goeltz

        

Chief Medical Officer

Jamie Dananberg

        

Chief Scientific Officer

Dan Marquess

        

President

Nathaniel David

        

VP - General Counsel

Tamara Tompkins

        

Browse more venture capital transactions:

Prev: 10/31/2016: Advanced Animal Diagnostics venture capital transaction
Next: 10/31/2016: CodeFights venture capital transaction

Share this article

Where The Data Comes From

Our team works diligently to report on every notable VC transaction. VC transactions reported here are sourced from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary